Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.22 USD
Change Today -0.21 / -3.87%
Volume 654.3K
BTX On Other Exchanges
Symbol
Exchange
BTX is not on other exchanges.
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

biotime inc (BTX) Snapshot

Open
$5.38
Previous Close
$5.43
Day High
$5.40
Day Low
$5.08
52 Week High
04/14/15 - $5.91
52 Week Low
05/12/14 - $2.21
Market Cap
434.1M
Average Volume 10 Days
337.8K
EPS TTM
$-0.56
Shares Outstanding
83.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTIME INC (BTX)

biotime inc (BTX) Related Businessweek News

No Related Businessweek News Found

biotime inc (BTX) Details

BioTime, Inc., a biotechnology company, engages in the research and product development in the field of regenerative medicine. The company focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including PureStem human embryonic progenitor cell lines; associated ESpan culture media; human embryonic stem cell lines; HyStem hydrogel products; and Hextend, a blood plasma volume expander for hypovolemia in surgery, emergency trauma, and other applications. The company’s clinical programs include OpRegen and OpRegen-Plus, which are in Phase I/IIa trial for the treatment of the dry form of age-related macular degeneration; AST-OPC1 that is in Phase I/IIa trial for spinal cord injuries; Renevia, which is in pivotal trial for HIV-related lipoatrophy; and AST-VAC2 that is in pre-clinical stage for non-small cell lung cancer. It is also developing Premvia, a hydrogel formulation of cross-linked thiol-modified hyaluronan and thiol-modified gelatin to manage wounds; ReGlyde, a cross-linked thiol-modified hyaluronan hydrogel to manage and protect tendon injuries; and PanC-Dx, a diagnostic product used to detect breast, bladder, and lung cancers, as well as mobile health software products. In addition, the company markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; VarElect, an application for prioritizing gene variants; and MalaCards, a database of human diseases, as well as analysis tools. Further, it develops cell based therapeutic products for diseases, such as neurological, cancer, age related macular degeneration, orthopedic, and age-related cardiovascular diseases. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.

117 Employees
Last Reported Date: 03/11/15
Founded in 1990

biotime inc (BTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $745.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $550.1K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $104.2K
Compensation as of Fiscal Year 2013.

biotime inc (BTX) Key Developments

BioTime, Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

BioTime, Inc. reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company’s total revenues were $1,887,535 against $1,892,485 a year ago. Loss from operations was $14,404,591 against $29,293,443 a year ago. Loss before income tax benefits was $14,976,252 against $29,335,719 a year ago. Net loss attributable to the company was $10,567,537 against $19,612,314 a year ago. Net loss attributable to the company's common shareholders was $10,620,326 against $19,612,314 a year ago. Basic and diluted net loss per common share was $0.14 against $0.35 a year ago. The decrease in net loss is primarily attributed to the $17,500,000 of IPR&D expense incurred during 2013. For the year, the company reported total revenue was $5,243,204 against $4,434,336 a year ago. Loss from operations was $50,682,574 against $55,985,186 a year ago. Loss before income tax benefits was $51,154,711 against $56,189,821 a year ago. Net loss attributable to the company was $36,411,660 against $43,882,835 a year ago. Net loss attributable to the company's common shareholders was $36,498,487 against $43,882,835 a year ago. Basic and diluted net loss per common share was $0.55 against $0.81 a year ago. The increase in revenue is primarily attributable to an increase in grant revenue, partially offset by a decrease in license fees. The decrease in net loss is primarily attributable to the $17.5 million of IPR&D expense incurred during 2013. Net loss attributable to the company includes losses from the company’s majority owned subsidiaries based upon the company percentage ownership of those subsidiaries.

BioTime Seeks Acquisitions

BioTime, Inc. (AMEX:BTX) has filed a shelf registration in the amount of $100 million. BioTime said, "We intend to use the net proceeds from the sale of our securities offered by this prospectus for general corporate purposes, including, without limitation, working capital, capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and businesses, and investments, including in our subsidiaries."

Aditya Mohanty Joins BioTime, Inc. as New Chief Operating Officer

On December 29, 2014, Aditya Mohanty joined BioTime, Inc. as its new Chief Operating Officer. Mr. Mohanty comes to the company from Shire plc, where he served in a number of executive positions, including as President/Head Regenerative Medicine from 2013 to 2014, as Senior Vice President, Business and Technical Operations from 2012 to 2013, as Global Franchise Head MPS from 2010 to 2012, and as Vice President of Operations/Product General Manager from 2005 to 2012. Mr. Mohanty was VP of Manufacturing and Operations at Transkaryotic Therapies, Inc. from 2002 to 2005 when it was acquired by Shire. Before joining Transkaryotic Therapies, Mr. Mohanty held a number of management positions at Baxter Healthcare Corporation, Bioscience Division from 1990 to 2002.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTX:US $5.22 USD -0.21

BTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cellular Dynamics International Inc $16.47 USD -0.03
Geron Corp $3.97 USD -0.10
Ocata Therapeutics Inc $6.98 USD -0.02
Organovo Holdings Inc $4.56 USD -0.16
ReproCELL Inc ¥690.00 JPY +6.00
View Industry Companies
 

Industry Analysis

BTX

Industry Average

Valuation BTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 77.6x
Price/Book 12.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 71.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIME INC, please visit www.biotimeinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.